Overall survival estimates among earlier cohorts stratified by donor type
| Donor . | AML97 . | Total Therapy 13/Total Therapy 14 . | ||||
|---|---|---|---|---|---|---|
| N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | |
| Sibling | 12 | 33 (10-59) | 33 (10-59) | 17 | 38 (16-60) | 15 (2.6-38) |
| Unrelated | 29 | 41 (24-58) | 38 (21-55) | 33 | 46 (28-61) | 36 (21-52) |
| Haploidentical | 9 | 33 (7.8-62) | 22 (3.4-51) | 7 | 29 (4.1-61) | 14 (0.7-47) |
| Combined | 50 | 38 (25-51) | 34 (21-47) | 57 | 41 (28-54) | 28 (17-40) |
| Donor . | AML97 . | Total Therapy 13/Total Therapy 14 . | ||||
|---|---|---|---|---|---|---|
| N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | |
| Sibling | 12 | 33 (10-59) | 33 (10-59) | 17 | 38 (16-60) | 15 (2.6-38) |
| Unrelated | 29 | 41 (24-58) | 38 (21-55) | 33 | 46 (28-61) | 36 (21-52) |
| Haploidentical | 9 | 33 (7.8-62) | 22 (3.4-51) | 7 | 29 (4.1-61) | 14 (0.7-47) |
| Combined | 50 | 38 (25-51) | 34 (21-47) | 57 | 41 (28-54) | 28 (17-40) |
OS indicates overall survival.